Genetic Ancestry Inference From Tumor Profiling Data of 100,000 Cancer Patients

ESHG 2022

May 10, 2023
Oncology
Presentation

Francisco De La Vega, Brooke Rhead, Yannick Pouliot, Sean Irvine, and Justin Guinney

Background/Objectives: The incidence and mortality of cancer vary widely across race and ethnicity due to a variety of factors. Cancer research has underrepresented non-White patients, thereby limiting our understanding of cancer biology in these populations. Given the missingness of race/ethnicity annotations in real-word (RW) data, inferring genetic ancestry from tumor sequencing can provide a more accurate substrate to investigate such disparities in this setting.

 

Methods: We inferred genetic ancestry from 100,000 de-identified records from cancer patients who underwent tumor genomic profiling with the Tempus xT next-generation sequencing assay (targeting 648 genes). We used ancestry informative markers overlapping assay capture regions to infer continental ancestry proportions: Africa, Amerindian, Europe, East Asia, and South Asia. Recognizing the complexity of ancestry and race relationships, we also imputed race/ethnicity categories using admixture thresholds based on literature.

 

Results: While most patients in our dataset are of European descent (72%), our RW cohort includes proportionally 4.7 and 3.8-fold more patients with substantial (>50%) African and Amerindian ancestry, correspondingly, compared with TCGA. We observed higher percentages of African ancestry patients with prostate, breast, and colorectal cancer (1.8-3.1%) and Amerindian ancestry patients with colorectal cancer (2.4%) compared to the overall cohort-level distributions (p < 0.05). Using imputation on subjects lacking race/ethnicity labels, we identified 60% and 121% more patients as likely Black and Hispanic/Latino, respectively.

 

Conclusion: Our results show that genetic ancestry inference from tumor profiling data can partially compensate for the missingness of race/ethnicity in RW data and allow research on biological race differences in cancer etiology and outcomes.